Details of a Researcher

HIRATA Aya

写真a

Affiliation: School of Medicine, Department of Preventive Medicine and Public Health (Shinanomachi)

Position: Assistant Professor/Senior Assistant Professor

Page Top ▲

Career 【 Display / hide 】

2009.04

-

2014.03

高槻赤十字病院, 検査部
2014.04

-

2015.03

大阪市立大学医学部附属病院, 中央臨床検査部
2019.04

-

2020.09

慶應義塾大学医学部衛生学公衆衛生学教室, 助教
2020.10

-

Present

慶應義塾大学医学部衛生学公衆衛生学教室 , 専任講師

Page Top ▲

Academic Background 【 Display / hide 】

2005.04

-

2009.03

Kyoto University, 医学部, 保健学科検査技術科学専攻

University, Graduated
2011.04

-

2013.03

Kyoto University, 大学院医学研究科, 専門職学位課程

Graduate School, Completed, Master's course
2015.04

-

2019.03

Keio University, 大学院医学研究科, 博士課程

Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

社会健康医学修士（専門職）, Kyoto University, 2013.03
博士（医学）, 慶應義塾大学, 2019.03

Page Top ▲

Research Keywords 【 Display / hide 】

公衆衛生、疫学、循環器疾患、動脈硬化、脂質、脂肪肝

Page Top ▲

Books 【 Display / hide 】

Encyclopedia of Cardiovascular Research and Medicine

Douglas B. Sawyer, Ramachandran S. Vasan 編集; Okamura T, Sugiyama D, Hirata T, Kuwabara K, Hirata A [他] 著, Elsevier, Oxford, 2017.12

Scope: Lipids and Cardiovascular Diseases: Epidemiologic Perspectives（分担執筆）
Lipids and Cardiovascular Diseases: Epidemiologic Perspectives

Okamura T., Sugiyama D., Hirata T., Kuwabara K., Hirata A., Encyclopedia of Cardiovascular Research and Medicine, 2017.01

　View Summary

During the past 70 years, a relationship between low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD) incidence has been established in many countries. Evidence of causality has been provided by the prevention of CHD by reduction of LDL-C, most notably with statins. These findings have made it possible to develop risk assessment charts for CHD and to detect high-risk individuals for early intervention. However, a causal relation between lipids and stroke, an adverse effect on noncoronary mortality such as that due to intraparenchymal hemorrhage, and the roles of lipid parameters other than LDL-C remain controversial.
- Access to Document (DOI)
FDA リスク&ベネフィットコミュニケーション: エビデンスに基づく健康・医療に関する指針（共訳）

バルークフィッシュホフ [他] 著, 中山健夫, 杉森裕樹監訳, 平田あや [他] 訳, 丸善出版, 2015.07

Page Top ▲

Papers 【 Display / hide 】

Metabolomics Profiles Alterations in Cigarette Smokers and Heated Tobacco Product Users

Harada Sei, Ohmomo Hideki, Matsumoto Minako, Sata Mizuki, Iida Miho, Hirata Aya, Miyagawa Naoko, Kuwabara Kazuyo, Kato Suzuka, Toki Ryota, Edagawa Shun, Sugiyama Daisuke, Sato Asako, Hirayama Akiyoshi, Sugimoto Masahiro, Soga Tomoyoshi, Tomita Masaru, Shimizu Atsushi, Okamura Tomonori, Takebayashi Toru

Journal of Epidemiology (Japan Epidemiological Association) 34 ( 9 ) 403 - 410 2024.09

ISSN 09175040

　View Summary

Background: Heated tobacco products (HTPs) have gained global popularity, but their health risks remain unclear. Therefore, the current study aimed to identify plasma metabolites associated with smoking and HTP use in a large Japanese population to improve health risk assessment.Methods: Metabolomics data from 9,922 baseline participants of the Tsuruoka Metabolomics Cohort Study (TMCS) were analyzed to determine the association between smoking habits and plasma metabolites. Moreover, alterations in smoking-related metabolites among HTP users were examined based on data obtained from 3,334 participants involved from April 2018 to June 2019 in a follow-up survey.Results: Our study revealed that cigarette smokers had metabolomics profiles distinct from never smokers, with 22 polar metabolites identified as candidate biomarkers for smoking. These biomarker profiles of HTP users were closer to those of cigarette smokers than those of never smokers. The concentration of glutamate was higher in cigarette smokers, and biomarkers involved in glutamate metabolism were also associated with cigarette smoking and HTP use. Network pathway analysis showed that smoking was associated with the glutamate pathway, which could lead to endothelial dysfunction and atherosclerosis of the vessels.Conclusion: Our study showed that the glutamate pathway is affected by habitual smoking. These changes in the glutamate pathway may partly explain the mechanism by which cigarette smoking causes cardiovascular disease. HTP use was also associated with glutamate metabolism, indicating that HTP use may contribute to the development of cardiovascular disease through mechanisms similar to those in cigarette use.
- Access to Document (DOI)
- CiNii Research
Risk Factors for Heart Failure and Coronary Artery Disease Mortality Based on the National Vital Statistics During a 25-Year Follow-up in Japan　― NIPPON DATA90 ―

Kubo Kota, Hirata Aya, Kadota Aya, Harada Akiko, Nakamura Yasuyuki, Hayakawa Takehito, Takashima Naoyuki, Fujiyoshi Akira, Okami Yukiko, Kita Yoshikuni, Okayama Akira, Miura Katsuyuki, Ueshima Hirotsugu, Okamura Tomonori, for the NIPPON DATA90 Research Group

Circulation Journal (The Japanese Circulation Society) 88 ( 9 ) 1478 - 1487 2024.08

ISSN 13469843

　View Summary

Background: Prevention of heart failure (HF) is a public health issue. Using the National Vital Statistics, we explored risk factors for HF and coronary artery disease (CAD) mortality.Methods and Results: Altogether, 7,556 Japanese individuals aged ≥30 years in 1990 were followed over 25 years; of these, 139 and 154 died from HF and CAD, respectively. In multivariable Cox proportional hazard analysis, common risk factors for CAD and HF mortality were hypertension (hazard ratio [HR] 1.48 [95% confidence interval {CI} 1.00–2.20] and 2.31 [95% CI 1.48–3.61], respectively), diabetes (HR 2.52 [95% CI 1.63–3.90] and 2.07 [95% CI 1.23–3.50], respectively), and current smoking (HR 2.05 [95% CI 1.27–3.31) and 1.86 [95% CI 1.10–3.15], respectively). Specific risk factors for CAD were male sex, chronic kidney disease, history of cardiovascular disease, and both abnormal T and Q waves, with HRs (95% CIs) of 1.75 (1.05–2.92), 1.78 (1.19–2.66), 2.50 (1.62–3.88), and 11.4 (3.64–36.0), respectively. Specific factors for HF were current drinking (HR 0.43; 95% CI 0.24–0.78) and non-high-density lipoprotein cholesterol (non-HDL-C; HR 0.81; 95% CI 0.67–0.98). There was an inverse association between non-HDL-C and HF in those aged ≥65 years (HR 0.71; 95% CI 0.56–0.90), but not in those aged <65 years.Conclusions: We identified common risk factors for HF and CAD deaths; a history of cardiovascular disease was a specific risk for CAD.
- Access to Document (DOI)
- CiNii Research
Validity assessment of self-reported medication use in a pharmacoepidemiologic study by comparison with prescription record review

YAJIMA Rina, MATSUMOTO Minako, IIDA Miho, HARADA Sei, SHIBUKI Takuma, HIRATA Aya, KUWABARA Kazuyo, MIYAGAWA Naoko, NAKAMURA Tomonori, OKAMURA Tomonori, TAKEBAYASHI Toru

Nihon Koshu Eisei Zasshi(JAPANESE JOURNAL OF PUBLIC HEALTH) (Japanese Society of Public Health) 71 ( 8 ) 430 - 437 2024.08

ISSN 05461766

　View Summary

Objectives　Although self-reported questionnaires are widely used to collect information on medication use in epidemiological studies, their validity for studies involving older adults has not been sufficiently assessed. This study evaluated the validity of self-reported medication use using questionnaires in comparison with drug notebooks.Methods　The study enrolled 370 older community dwellers who participated in an aging sub-study survey of the Tsuruoka Metabolomics Cohort Study between April 2019 and March 2021. Medication use was assessed by comparing self-reported questionnaire data with drug notebook records. We analyzed medications used for hypertension, dyslipidemia, myocardial infarction, angina, diabetes, rheumatism, osteoporosis/metabolic bone disease, constipation, anxiety/depression, dementia, asthma, allergy, thrombosis, and thyroid disease. Moreover, gastrointestinal (GI) medications, steroids, and antipyretic analgesics were assessed, and data on injectable medications for osteoporosis/metabolic bone disease was collected. Using drug notebook records, we identified regular medication users by assessing whether they had received oral medication prescriptions covering over 28 days and took the medication within the 90 days preceding the day of their survey. To define medication categories, we used Anatomical Therapeutic Chemical (ATC) classification codes. Sensitivity, specificity, and kappa statistics were calculated for each medication using drug notebooks as standards. Those who did not bring their drug notebooks on the day of the survey were defined as non-medication users.Results　The mean age (standard deviation) of the 370 participants (146 men and 224 women) was 73.3 (4.0) years. The sensitivity and specificity for each medication were as follows: hypertension (0.97, 0.97), dyslipidemia (0.93, 0.98), myocardial infarction (0.24, 0.99), diabetes (0.94, 1.00), rheumatism (1.00, 1.00), osteoporosis/metabolic bone disease (0.82, 0.99), constipation (0.71, 0.98), GI conditions (0.63, 0.97), anxiety/depression (0.36, 1.00), dementia (0.67, 1.00), asthma (0.67, 0.98), allergy (0.57, 0.99), thrombosis (0.88, 0.98), steroids (0.80, 0.99), thyroid disease (1.00, 1.00) and antipyretic analgesics (0.75, 0.96).Conclusions　Although sensitivity and specificity differed by medication categories, the results of our population-based cohort study suggested that self-reported questionnaires on medication use among older adults are valid, especially for medications with high sensitivity (≥ 0.8).
- Access to Document (DOI)
- CiNii Research
Study Profile of the Tsuruoka Metabolomics Cohort Study (TMCS)

Harada Sei, Iida Miho, Miyagawa Naoko, Hirata Aya, Kuwabara Kazuyo, Matsumoto Minako, Okamura Tomonori, Edagawa Shun, Kawada Yoko, Miyake Atsuko, Toki Ryota, Akiyama Miki, Kawai Atsuki, Sugiyama Daisuke, Sato Yasunori, Takemura Ryo, Fukai Kota, Ishibashi Yoshiki, Kato Suzuka, Kurihara Ayako, Sata Mizuki, Shibuki Takuma, Takeuchi Ayano, Kohsaka Shun, Sawano Mitsuaki, Shoji Satoshi, Izawa Yoshikane, Katsumata Masahiro, Oki Koichi, Takahashi Shinichi, Takizawa Tsubasa, Maruya Hiroshi, Nishiwaki Yuji, Kawasaki Ryo, Hirayama Akiyoshi, Ishikawa Takamasa, Saito Rintaro, Sato Asako, Soga Tomoyoshi, Sugimoto Masahiro, Tomita Masaru, Komaki Shohei, Ohmomo Hideki, Ono Kanako, Otsuka-Yamasaki Yayoi, Shimizu Atsushi, Sutoh Yoichi, Hozawa Atsushi, Kinoshita Kengo, Koshiba Seizo, Kumada Kazuki, Ogishima Soichi, Sakurai-Yageta Mika, Tamiya Gen, Takebayashi Toru

Journal of Epidemiology (Japan Epidemiological Association) 34 ( 8 ) 393 - 401 2024.08

ISSN 09175040

　View Summary

The Tsuruoka Metabolomics Cohort Study (TMCS) is an ongoing population-based cohort study being conducted in the rural area of Yamagata Prefecture, Japan. This study aimed to enhance the precision prevention of multi-factorial, complex diseases, including non-communicable and aging-associated diseases, by improving risk stratification and prediction measures. At baseline, 11,002 participants aged 35–74 years were recruited in Tsuruoka City, Yamagata Prefecture, Japan, between 2012 and 2015, with an ongoing follow-up survey. Participants underwent various measurements, examinations, tests, and questionnaires on their health, lifestyle, and social factors. This study uses an integrative approach with deep molecular profiling to identify potential biomarkers linked to phenotypes that underpin disease pathophysiology and provide better mechanistic insights into social health determinants. The TMCS incorporates multi-omics data, including genetic and metabolomic analyses of 10,933 participants, and comprehensive data collection ranging from physical, psychological, behavioral, and social to biological data. The metabolome is used as a phenotypic probe because it is sensitive to changes in physiological and external conditions. The TMCS focuses on collecting outcomes for cardiovascular disease, cancer incidence and mortality, disability and functional decline due to aging and disease sequelae, and the variation in health status within the body represented by omics analysis that lies between exposure and disease. It contains several sub-studies on aging, heated tobacco products, and women’s health. This study is notable for its robust design, high participation rate (89%), and long-term repeated surveys. Moreover, it contributes to precision prevention in Japan and East Asia as a well-established multi-omics platform.
- Access to Document (DOI)
- CiNii Research
Evaluation of Medication Adherence Among Prevalent Users in Hypertension, Dyslipidemia, and Diabetes Using Health Insurance Claims: A Population-Based Cohort Study in Japan

Matsumoto, M; Harada, S; Ikuta, H; Iida, M; Kato, S; Sata, M; Shibuki, T; Ishibashi, Y; Miyagawa, N; Hisamatsu, M; Hirata, A; Kuwabara, K; Takeuchi, A; Sugiyama, D; Suzuki, S; Nakamura, T; Okamura, T; Takebayashi, T

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 33 ( 8 ) 2024.08

ISSN 1053-8569
- Access to Document (DOI)

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

The utility of fatty liver index

Hirata, Aya

科学研究費補助金研究成果報告書 2021
Exploring metabolic markers for elevated BMI based on differences in metabolic profiles between Japan and the United States.

Hirata, Aya

科学研究費補助金研究成果報告書 2021

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

【冠動脈疾患のリスク管理のフロントライン】冠動脈疾患イベントリスクをどう評価する?

岡村智教, 平田あや, 桑原和代

循環器ジャーナル ((株)医学書院) 67 ( 4 ) 508 - 515 2019.10

ISSN 2432-3284

　View Summary

＜文献概要＞Point　・個々のリスクファクターではなく,複数のリスクファクターを組み合わせて冠動脈疾患の発症リスクを包括的に評価する必要がある.・特定健診などでスクリーニングするのは,冠動脈疾患そのものではなく冠動脈疾患を発症する可能性が高いハイリスク者であり,そのためにも包括的リスク評価が重要である.
【動脈硬化の早期診断法と予防対策-健康寿命延伸をめざして】発症予測と絶対リスク

平田あや, 岡村智教

カレントテラピー ((株)ライフメディコム) 36 ( 11 ) 1062 - 1067 2018.11

ISSN 0287-8445
【脂質代謝異常と循環器疾患】診る　脂質異常症と冠動脈疾患　わが国の疫学研究から

平田あや, 岡村智教

Heart View ((株)メジカルビュー社) 22 ( 7 ) 612 - 618 2018.07

ISSN 1342-6591
【動脈・静脈の疾患(上)-最新の診断・治療動向-】動脈・静脈疾患の疫学　わが国における血管疾患の疫学

平田あや, 岡村智教

日本臨床 ((株)日本臨床社) 75 ( 増刊4 動脈・静脈の疾患(上) ) 37 - 42 2017.05

ISSN 0047-1852

Page Top ▲

Presentations 【 Display / hide 】

都市住民における生活習慣と腎機能低下の進行との関連　神戸研究

平田あや, 東山綾, 平田匠, 杉山大典, 桑原和代, 佐田みずき, 西田陽子, 久保佐智美, 久保田芳美, 門田文, 西川智文, 宮松直美, 宮本恵宏, 岡村智教

日本公衆衛生学会総会抄録集,

2019.10
,
日本公衆衛生学会
都市部住民における推定24時間尿中NaとNa/Kの腎機能低下リスク　神戸研究

服部浩子, 梅本かおり, 野澤美樹, 中越奈津子, 東山綾, 西田陽子, 久保佐智美, 久保田芳美, 平田匠, 宮松直美, 平田あや, 佐田みずき, 桑原和代, 杉山大典, 岡村智教

日本公衆衛生学会総会抄録集,

2019.10
,
日本公衆衛生学会
都市住民における出生体重と循環器疾患の危険因子との関連　神戸研究

梅本かおり, 東山綾, 平田匠, 杉山大典, 桑原和代, 平田あや, 佐田みずき, 西田陽子, 久保佐智美, 久保田芳美, 門田文, 西川智文, 宮松直美, 宮本恵宏, 岡村智教

日本公衆衛生学会総会抄録集,

2019.10
,
日本公衆衛生学会
健常人における心拍数およびダブルプロダクトの規定要因　神戸研究

中越奈津子, 野澤美樹, 服部浩子, 平田あや, 佐田みずき, 久保佐智美, 東山綾, 西田陽子, 久保田芳美, 平田匠, 宮松直美, 桑原和代, 杉山大典, 岡村智教

日本公衆衛生学会総会抄録集,

2019.10
,
日本公衆衛生学会
飲酒の有無によるFatty liver indexの脂肪肝診断能に関する検討

平田あや, 杉山大典, 桑原和代, 岡村智教

日本アルコール・薬物医学会雑誌,

2019.08
,
(一社)日本アルコール・アディクション医学会

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Cross-sectional and longitudinal studies on the relationship between blood metal element concentrations and health status and their determinants in urban residents

2024.04

-

2029.03

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), No Setting

　View Summary

本研究は、都市部住民の血中微量金属元素濃度と動脈硬化性疾患およびその危険因子との関連を明らかにし、予防のための新しい知見を得ることを目的とする。神戸市の40歳以上の住民1,117人を対象に、血清中の抗酸化作用を持つ微量金属元素を測定し、動脈硬化性疾患の危険因子やCAVIとの関連を横断・縦断研究で検討する。また、追跡期間中の生活習慣病発症をアウトカムとしたコホート研究を行う。神戸研究では生活習慣や社会経済・心理要因など多くの項目を調査しており、微量金属元素摂取の規定要因や複合曝露による影響を明らかにすることで、動脈硬化性疾患の予防対策に貢献できる。
Epidemiological study to generate evidence for the introduction of a program to evaluate early stage renal dysfunction in health checkups

2024.04

-

2027.03

基盤研究(B), Principal investigator
Research on the significance of sleep interventions for prevention of cardiovascular diseases in the elderly and middle-aged population

2023.04

-

2026.03

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), No Setting

　View Summary

高齢者および中高年者における睡眠の循環器疾患リスクに関する疫学的エビデンスを創出することを目的とし、高齢者・中高年者において客観的に測定した睡眠指標（睡眠時間・睡眠効率・中途覚醒時間・中途覚醒率）が循環器疾患の危険因子や潜在性動脈硬化・心不全の指標と関連するか、高齢者の睡眠障害は循環器疾患リスクを増加させるかについて明らかにする。本研究の実施により、高齢者および中高年者に対する循環器疾患予防を目的とした睡眠の介入可能性について有用な知見を得ることができる。
脂質に着目した脳・心血管疾患の個別化予防実現のためのゲノム・メタボローム疫学研究

2022.04

-

2024.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, 若手研究, Principal investigator
変性リポ蛋白を含む脂質プロフィールと脳・心血管疾患の関連、その規定要因の解明

2021.04

-

2026.03

Keio University, Grant-in-Aid for Scientific Research (A), No Setting

　View Summary

Lectin-like oxidized LDL Receptor (LOX-1)は内皮細胞の変性LDLの受容体であり、変性LDL、変性LDLの催動脈硬化作用はLOX-1を介している可能性がある。本研究では複数のコホート集団の疫学研究で、通常の血中脂質検査に加えて変性LDL、変性HDLと脳・心血管疾患との関連を評価し、病型の決定にこれらの因子がどのように影響しているかを明らかにする。また変性リポ蛋白の生活習慣上の規定要因を血中等のメタボローム解析も含めて検証する。これにより将来、変性リポ蛋白を治療ターゲットにした介入研究への橋渡しが可能となり、創薬や予防方法の開発に発展させることが可能である。

display all >>

Page Top ▲

Awards 【 Display / hide 】

日本アルコール・アディクション医学会学術奨励賞

2024.09
第56回日本循環器病予防学会学術集会 Young Investigator’s Award優秀賞

2020.12, Fatty liver indexとCAVIの関連における血中アミノ酸の疫学的検討：鶴岡メタボロームコホート研究
第50回日本動脈硬化学会総会・学術集会　最優秀ポスター賞

2018.07, 全国9コホート43,407名の統合解析による超高値HDL-Cと動脈硬化性心血管疾患との関連：The EPOCH-JAPAN study